


In the Claims

Please cancel claims 18, 26 and 27 without prejudice to the filing of future continuing applications.

Please substitute the following claims 1, 20, 28 and 29 for the claims 1, 20, 28 and 29 now pending in the above-identified application.

1. (Currently Amended) A compound represented by the formula:



wherein A ring denotes a non-aromatic 5 -membered nitrogen-containing heterocyclic ring ~~which contains~~ of at least one nitrogen atom ~~in addition to and~~ carbon atoms and may have a further substituent selected from the group consisting of:

- an optionally substituted hydrocarbon group,
- an optionally halogenated lower alkoxy group,
- an optionally halogenated lower alkylthio group,
- a halogen atom,
- an aryloxy group,
- a lower alkanoyl group,
- an arylcarbonyl group,
- a lower alkanoyloxy group,
- an arylcarbonyloxy group,
- a carboxyl group,
- a lower alkoxycarbonyl group,
- a carbamoyl group,
- a thiocarbamoyl group,
- a mono-lower alkylcarbamoyl group,
- a di-lower alkylcarbamoyl group,

a C₆₋₁₀ aryl-carbamoyl group,
an amidino group,
an imino group,
an amino group,
a mono-lower alkylamino group,
a di-lower alkylamino group,
a 3- to 6-membered cyclic amino group optionally containing 1 to
3 heteroatoms selected from the group consisting of oxygen
atom, sulfur atom and nitrogen atom, in addition to carbon
atoms and one nitrogen atom,
an alkylenedioxy group,
a hydroxy group,
a nitro group,
a cyano group,
a mercapto group,
a sulfo group,
a sulfinio group,
a phosphono group,
a sulfamoyl group,
a mono-lower alkylsulfamoyl group,
a di-lower alkylsulfamoyl group,
an arylthio group,
a lower alkylsulfinyl group,

an arylsulfinyl group,
a lower alkylsulfonyl group, and
an aryl sulfonyl group;

B ring denotes a benzene ring which may be further substituted;

C ring denotes a dihydrofuran ring which may be further substituted; and

R denotes hydrogen atom or an acyl group;

or a salt thereof.

2. (Previously Presented) The compound according to claim 1, wherein A ring is a non-aromatic 5-membered nitrogen-containing heterocyclic ring which may be further substituted with an optionally substituted hydrocarbon group.


3. (Previously Presented) The compound according to claim 1, wherein A ring is a non-aromatic 5 -membered nitrogen-containing heterocyclic ring which may be further substituted with an optionally substituted lower alkyl group.

4. (Previously Presented) The compound according to claim 1, wherein A ring is a non-aromatic 5 -membered nitrogen-containing heterocyclic ring which may be further substituted with a lower alkyl group.

Claim 5 (Cancelled)

6. (Original) The compound according to claim 1, wherein B ring is a wholly substituted benzene ring.

7. (Original) The compound according to claim 1 which is a compound represented by the formula:




wherein R^4 and R^5 are the same or different and each denotes hydrogen atom, a halogen atom, hydroxy group, amino group, or an optionally substituted hydrocarbon group which may be via oxygen atom, nitrogen atom or sulfur atom, and other symbols are as defined in claim 1, provided that both R^4 and R^5 do not denote hydrogen atom at the same time, or a salt thereof.

8. (Original) The compound according to claim 7, wherein R^4 and R^5 are the same or different and each is a lower alkyl group or a lower alkoxy group.

9. (Original) The compound according to claim 7, wherein R^4 and R^5 are a lower alkyl group.

10. (Previously Presented) The compound according to claim 1 which is a compound represented by the formula:



wherein R^1 and R^2 are the same or different and each denotes hydrogen atom, an optionally esterified or amidated carboxyl group or an optionally substituted hydrocarbon group, R^3 denotes hydrogen atom, an optionally substituted hydrocarbon group or an optionally substituted amino group, R^4 and R^5 are the same or different and each denotes hydrogen atom, a halogen atom, hydroxy group, amino group, or an optionally substituted hydrocarbon group which may be via oxygen atom, nitrogen atom or sulfur atom and other symbols are as defined in claim 1, or a salt thereof.

11. (Previously Presented) The compound according to claim 10, wherein R^1 is a lower alkyl group, R^2 is a lower alkyl group which may be substituted with an optionally substituted cyclic amino, a halogen atom or a hydroxy, and R^3 is hydrogen atom or an optionally substituted phenyl group.

12. (Previously Presented) The compound according to claim 10, wherein R^1 is a lower alkyl group, R^2 is a lower alkyl group which may be substituted with an optionally substituted cyclic amino group, a halogen atom or a hydroxy, R^3 is hydrogen atom or an optionally substituted phenyl group, R^4 and R^5 are a lower alkyl group, and A ring is a non-aromatic 5-membered nitrogen-containing heterocyclic ring which may be further substituted with a lower alkyl group.

13. (Previously Presented) The compound according to claim 10, wherein R¹ is a lower alkyl group, R² is a lower alkyl group which may be substituted with an optionally substituted cyclic amino group, a halogen atom or a hydroxy, R³ is hydrogen atom or an optionally substituted phenyl group, R⁴ and R⁵ are independently a lower alkyl group, and A ring is a non-aromatic 5-membered nitrogen-containing heterocyclic ring which may be further substituted with a lower alkyl group.

14. (Original) The compound according to claim 1 which is 1,6,7,8-tetrahydro-2,2,4,5-tetramethyl-1-(4-methylphenyl)-2H-furo[3,2-e]indole or a salt thereof.


15. (Original) The compound according to claim 1 which is 1,6,7,8-tetrahydro-2,4,5-trimethyl-2-[(4-phenylpiperidino)methyl]-2H-furo[3,2-e]indole or a salt thereof.

16. (Original) The compound according to claim 1 which is 1,6,7,8-tetrahydro-2,4,5,7,7-pentamethyl-2-[(4-phenylpiperidino)methyl]-2H-furo[3,2-e]indole or a salt thereof.

17. (Original) The compound according to claim 1 which is N-(diphenylmethyl)-1-[(1,6,7,8-tetrahydro-2,4,5,7,7-pentamethyl-2H-furo[3,2-e]indol-2-yl)methyl]-4-piperidineamine or a salt thereof.

Claim 18 (Cancelled)

19. (Original) A process for preparing the compound according to claim 1 which comprises ring-closing a substituent X and hydroxy group on B ring of a compound represented by the formula:




wherein X denotes an optionally substituted allyl group, and other symbols are as defined in claim 1, or a salt thereof.

20. (Currently Amended) A pharmaceutical composition which comprises a compound of claim 1 or a salt thereof, ~~or a prodrug thereof~~ and a pharmacologically acceptable carrier.


Claims 21-27 (Cancelled)

28. (Currently Amended) A method for ~~preventing or~~ treating restenosis after percutaneous transluminal coronary angioplasty which comprises administering a compound represented by the formula:



wherein Aa ring denotes a non-aromatic 5-membered nitrogen-containing heretocyclic ring which may be further substituted, Ba ring denotes a benzene ring which may be further substituted, Ca ring denotes a dihydrofuran ring which may be further substituted, and Ra denotes hydrogen atom or an acyl group, or a salt thereof, ~~or a prodrug thereof~~ to a mammal.

29. (Currently Amended) A method for ~~inhibiting lipid peroxidation~~ treating Alzheimer's disease which comprises administering a compound represented by the formula:



wherein Aa ring denotes a non-aromatic 5- membered nitrogen-containing heretocyclic ring which may be further substituted, Ba ring denotes a benzene ring which may be further substituted, Ca ring denotes a dihydrofuran ring which may be further substituted, and Ra denotes hydrogen atom or an acyl group, or a salt thereof, ~~or a prodrug thereof~~ to a mammal.

Claims 30-33 (Cancelled)